| Literature DB >> 29576738 |
Edyta Cędrowska1, Marek Pruszynski1, Agnieszka Majkowska-Pilip1, Sylwia Męczyńska-Wielgosz1, Frank Bruchertseifer2, Alfred Morgenstern2, Aleksander Bilewicz1.
Abstract
The 225Ac radioisotope exhibits very attractive nuclear properties for application in radionuclide therapy. Unfortunately, the major challenge for radioconjugates labelled with 225Ac is that traditional chelating moieties are unable to sequester the radioactive daughters in the bioconjugate which is critical to minimize toxicity to healthy, non-targeted tissues. In the present work, we propose to apply TiO2 nanoparticles (NPs) as carrier for 225Ac and its decay products. The surface of TiO2 nanoparticles with 25 nm diameter was modified with Substance P (5-11), a peptide fragment which targets NK1 receptors on the glioma cells, through the silan-PEG-NHS linker. Nanoparticles functionalized with Substance P (5-11) were synthesized with high yield in a two-step procedure, and the products were characterized by transmission electron microscopy (TEM), dynamic light scattering (DLS) and thermogravimetric analysis (TGA). The obtained results show that one TiO2-bioconjugate nanoparticle contains in average 80 peptide molecules on its surface. The synthesized TiO2-PEG-SP(5-11) conjugates were labelled with 225Ac by ion-exchange reaction on hydroxyl (OH) functional groups on the TiO2 surface. The labelled bioconjugates almost quantitatively retain 225Ac in phosphate-buffered saline (PBS), physiological salt and cerebrospinal fluid (CSF) for up to 10 days. The leaching of 221Fr, a first decay daughter of 225Ac, in an amount of 30% was observed only in CSF after 10 days. The synthesized 225Ac-TiO2-PEG-SP(5-11) has shown high cytotoxic effect in vitro in T98G glioma cells; therefore, it is a promising new radioconjugate for targeted radionuclide therapy of brain tumours.Entities:
Keywords: 225Ac; Nanomedicine; Substance P; Targeted radionuclide therapy; Titanium dioxide nanoparticles; Treatment cancer cells
Year: 2018 PMID: 29576738 PMCID: PMC5861168 DOI: 10.1007/s11051-018-4181-y
Source DB: PubMed Journal: J Nanopart Res ISSN: 1388-0764 Impact factor: 2.253
Fig. 1SEM (a) and TEM (b) images of bare TiO2 nanoparticles
Fig. 2Functionalization of titanium dioxide nanoparticles with PEG-SP(5-11)
Fig. 3Thermograms of bare TiO2 NPs and TiO2 NPs functionalized with silane-PEG-SP(5-11)
Hydrodynamic diameter and zeta (ζ) potential of bare and functionalized TiO2 NPs (pH = 7.4, PB buffer)
| Nanoparticles | Hydrodynamic diameter | Zeta ( |
|---|---|---|
| TiO2 | 76.02 ± 5.54 | − 23.2 |
| TiO2-silane-PEG-SP(5-11) | 98.78 ± 4.50 | − 28.5 |
Retention of 225Ac and 221Fr on TiO2-silane-PEG-SP(5-11) NPs radiolabelled with 225Ac
| Solution | 221Fr retention (%) | |||
|---|---|---|---|---|
| 24 h | 48 h | 72 h | 96 h | |
| PBS (pH = 7.4) | 97.7 | 98.9 | 96.8 | 98.8 |
| Physiological salt (0.9% NaCl) | 98.5 | 98.4 | 93.3 | 94.8 |
| Cerebrospinal fluid (CSF) | 78.2 | 70.6 | 68.5 | – |
Fig. 4Metabolic activity (MTT assay) of T98G cells treated with different radioactivities of Ac-TiO2-silane-PEG (a) and Ac-TiO2-silane-PEG-SP(5-11) (b) NPs for 48, 72 and 96 h. Data are expressed as percent of control and the mean ± SD from three independent experiments
Fig. 5Metabolic activity (MTT assay) of T98G cells treated with different concentration of non-radiolabelled TiO2 (a) and TiO2-silane-PEG-SP(5-11) (b) NPs for 48, 72 and 96 h. Data are expressed as percent of control and the mean ± SD from three independent experiments